Avalon Ventures and GSK add two more companies to their launch list of early-stage life-science companies.
Avalon Ventures announced on Sept. 22, 2014 the launch of two new companies formed through its collaboration with GSK to fund and launch early-stage life-science companies, providing a total of ten new companies with up to $495 million through preclinical proof of concept. Sitari Pharmaceuticals, established in November 2013, was the first company launched through this collaboration and is targeting the transglutaminase 2 (TG2) pathway for the development of treatments for multiple disease indications, with an initial focus on celiac disease.
Avalon and GSK will provide its two new companies, Silarus Therapeutics and Thyritope Biosciences, with up to $10 million each in Series A financing and R&D support. Silarus and Thyritope will be located in San Diego at COI Pharmaceuticals, a company that was established by Avalon to provide operational support, an R&D facility, and a leadership team to its life-science portfolio companies.
Silarus Therapeutics is developing therapeutics targeting erythroferrone, a hormone that regulates iron supply for red blood cell production, for the treatment of iron deficiency and iron overload disorders.
Thyritope Biosciences is developing therapeutics that target thyroid stimulating autoantibodies, which are the causative drivers of the hyperthyroidism and orbitopathy that is associated with Graves’ disease. Graves’ disease is an autoimmune disorder caused by antibodies that overstimulate the thyroid, causing excessive thyroid hormone production. These antibodies stimulate the tissue around the eyes, resulting in an increase of orbital fat and extraocular muscle volume which causes the bulging of the eyes characteristic of Graves’ orbitopathy.
Source: Avalon
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.